Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Sensei Biotherapeutics (NASDAQ: SNSE) announced its participation in two key investor conferences in September 2022, aimed at exploring the latest in immuno-oncology developments.

The conferences are:

• Citi’s 17th Annual Biopharma Conference (September 7-8, Boston, MA)
• Wells Fargo’s 2022 Healthcare Conference (September 7-9, Boston, MA)

Interested portfolio managers and analysts can arrange meetings with company management through their respective representatives.

BOSTON, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer, today announced that Company management will participate in the following investor conferences in September 2022:

Citi’s 17^th Annual Biopharma Conference
September 7^th-8^th
Boston, MA

Wells Fargo’s 2022 Healthcare Conference
September 7^th-9^th
Boston, MA

Portfolio managers and analysts who would like to request a meeting with management should contact their representative at the respective hosting firms.

About Sensei Biotherapeutics
Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer. Sensei has designed two unique approaches to develop highly selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors, and the ImmunoPhage™ platform, which trains new T cells to recognize and kill malignant cells. Using its TMAb platform, the company is developing SNS-101, a fully human antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also using its platforms to develop other preclinical programs targeting multiple solid tumor indications. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com

FAQ

What conferences will Sensei Biotherapeutics attend in September 2022?

Sensei Biotherapeutics will participate in Citi’s 17th Annual Biopharma Conference from September 7-8 and Wells Fargo’s 2022 Healthcare Conference from September 7-9.

Where are the investor conferences for Sensei Biotherapeutics located?

Both investor conferences will take place in Boston, MA.

How can analysts request meetings with Sensei Biotherapeutics management during the conferences?

Analysts and portfolio managers can request meetings by contacting their representative at the hosting firms.

What is the focus of Sensei Biotherapeutics?

Sensei Biotherapeutics focuses on discovering and developing next-generation therapeutics for cancer through immuno-oncology.

What is the stock symbol for Sensei Biotherapeutics?

The stock symbol for Sensei Biotherapeutics is SNSE.